Efficacy Study of a Standardized Pollen Extract Preparation (Cernilton) to Treat Inflammatory Chronic Prostatitis-Chronic Pelvic Pain Syndrome (CP-CPPS)

Last updated: November 4, 2020
Sponsor: University of Giessen
Overall Status: Completed

Phase

3

Condition

Sexually Transmitted Diseases (Stds)

Prostate Disorders

Gynecological Infections

Treatment

N/A

Clinical Study ID

NCT00919893
4015497
  • Ages 18-65
  • Male

Study Summary

In this placebo controlled study the safety and efficacy of Cernilton, a standardized pollen extract, in men with inflammatory chronic prostatitis-chronic pelvic pain syndrome was investigated. The purpose of this study is to determine whether Cernilton is safe and effective in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • men between 18 and 65 years
  • symptoms of pelvic pain for at least 3 months during the 6 months before study entry
  • a score in the pain domain of the German validated version of the NIH chronicprostatitis symptom index (NIH-CPSI) of 7 or higher
  • leukocytes of 10 or more in post prostate massage urine

Exclusion

Exclusion Criteria:

  • urinary tract infection
  • acute bacterial or chronic bacterial prostatitis
  • history of urethritis with discharge 4 weeks prior to study entry
  • a history of epididymitis or sexually transmitted disease
  • residual urine volume of more than 50 mL due to bladder outlet obstruction
  • indication for or history of prostate surgery including prostate biopsy
  • treatment with phytotherapeutic agents
  • alpha-blocker agents or antimicrobial substances with prostatic penetration 4 weeksprior to study entry
  • treatment with agents influencing intraprostatic hormone metabolism 6 months prior tostudy entry

Study Design

Total Participants: 139
Study Start date:
December 01, 1999
Estimated Completion Date:
January 31, 2004

Study Description

We conducted a multicenter, randomized, double-blind, placebo-controlled trial to assess safety and efficacy of Cernilton, a standardized pollen extract, in men with inflammatory CP-CPPS (National Institutes of Health (NIH) type IIIA). Participants were randomized to Cernilton or placebo for 12 weeks and were evaluated using the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) individual domains and total score, the number of leukocytes in post prostatic massage urine, the International Prostate Symptom Score (IPSS) and the sexuality domain of a life satisfaction questionnaire at baseline and after 6 and 12 weeks.

Connect with a study center

  • Justus-Liebig-University

    Giessen, D-35392
    Germany

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.